Figure 5.
Concentration-dependent adaptive dose matrix optimization of paired reagent combinations was achieved by adaptively changing the concentrations of reagents after assessing the inhibition of IL-1β expression. A p38 MAPK inhibitor (SB203580) and an Iκ Kinase inhibitor (IKKi) (a) or an iron chelator (SIH) (d) were assessed alone and as paired combinations. Potential synergy of the SB203580 & IKKi (c) and SB203580 & SIH (f) combinations were revealed by subtraction of simple additive effects ((b) and (e); calculated from single reagent data in the absence of the other reagent respectively) of the respective combinations from the experimental data (a) & (d). Synergistic inhibition of IL-1β expression was revealed with the combinations of SB203580 & IKKi (c) and SB203580 & SIH (f) as an ‘extra’ inhibition additional to the additive inhibitions of the individual reagents taken together.